Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 2Phase EARLY_PHASE1 1Phase 3 1

Status

Recruiting 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Classical hematology 2Breast 2Thoracic 1Sarcoma 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 226Breast Neoplasms 223Prostatic Neoplasms 163Multiple Myeloma 147Neoplasms 130Leukemia, Myeloid, Acute 117Colorectal Neoplasms 117Lung Neoplasms 112Neoplasm Metastasis 95Squamous Cell Carcinoma of Head and Neck 90Carcinoma, Hepatocellular 88Melanoma 83Lymphoma 81Triple Negative Breast Neoplasms 74Pancreatic Neoplasms 73Ovarian Neoplasms 72Sarcoma 66Lymphoma, Large B-Cell, Diffuse 63Carcinoma, Renal Cell 63Brain Neoplasms 62Recurrence 58Head and Neck Neoplasms 57Stomach Neoplasms 54Precursor Cell Lymphoblastic Leukemia-Lymphoma 54Leukemia, Lymphocytic, Chronic, B-Cell 53Urinary Bladder Neoplasms 52Hematologic Neoplasms 52Lymphoma, Non-Hodgkin 51Small Cell Lung Carcinoma 50Endometrial Neoplasms 47

Interventions

Tretinoin 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1tislelizumab 1talazoparib 1sarilumab 1pexidartinib 1pertuzumab 1pembrolizumab 1patritumab 1olaparib 1niraparib 1neratinib 1ganitumab 1durvalumab 1dostarlimab 1cemiplimab 1abemaciclib 1Trastuzumab 1Standard of Care 1STA 9090 1SGN-LIV1A 1Paclitaxel 1Oxaliplatin 1MK 2206 1Letrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Pathologic Complete Response × 90 days × Clear all
NCT07586813 2026-05-14

N01-A-PICIT-GI

Peking University People's Hospital

Phase 2 Recruiting
220 enrolled
Classical hematologyGastrointestinal

Pathologic Complete Response, Digestive System Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Thrombocytopenia, Colorectal Neoplasms

NCT07586826 2026-05-14

N01-A-PICIT-GT

Peking University People's Hospital

Phase 2 Recruiting
220 enrolled
BreastClassical hematologyGynecologicThoracic

Pathologic Complete Response, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thrombocytopenia, Endometrial Neoplasms

NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer(CONTROL-01)

The Affiliated Hospital of Qingdao University

Phase 2 Recruiting
35 enrolled
Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡